Loading clinical trials...
Loading clinical trials...
A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
MEI Pharma, Inc.
Collaborators
NCT06846671 · CLL, Chronic Lymphocytic Leukemia
NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more
NCT07030400 · Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)
NCT06859424 · AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), and more
NCT05589896 · Acute Leukemia, Acute Lymphoblastic Leukemia, and more
Dana Farber Cancer Institute
Boston, Massachusetts
Stony Brook University
Stony Brook, New York
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions